½ÃÀ庸°í¼­
»óǰÄÚµå
1463658

¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå : Áö¿ª ºÐ¼® - Á¦Ç°º°, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(-2030³â)

Asia Pacific Cerebrospinal Fluid Management Market Forecast to 2030 - Regional Analysis - by Product (CSF Shunts and CSF Drainage Systems) and End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 82 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº 2022³â¿¡ 3¾ï 8,953¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 6¾ï 1,354¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 5.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½Å°æ Áúȯ Ä¡·á¿¡¼­ ¼ö¾× °ü¸®¿¡ ´ëÇÑ °ü½É Áõ°¡´Â ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀ» µÞ¹Þħ

CSF ¸Å°³º¯¼ö´Â ¼ºÀΠȯÀÚ¿¡¼­ ½Å°æ ÁúȯÀÇ ¹ÙÀÌ¿À¸¶Ä¿·Î ³Î¸® Æò°¡µË´Ï´Ù. CSFÀÇ ¼øÈ¯ ¸¶ÀÌÅ©·Î RNA´Â ´Ù¾çÇÑ ½Å°æ ÁúȯÀÇ Áø´Ü¿¡ À¯¸ÁÇÑ ¹ÙÀÌ¿À ¸¶Ä¿ÀÔ´Ï´Ù. ÆÄŲ½¼º´(PD), ¾ËÃ÷ÇÏÀ̸Ӻ´(AD), °£Áú, °æ·Ã µîÀÇ ½Å°æ Áúȯ¿¡¼­´Â Á¾Á¾ CSF ÆÄ¶ó¹ÌÅͰ¡ º¯ÇÕ´Ï´Ù. Nature' ÀâÁö¿¡ °ÔÀçµÈ ³í¹®¿¡ µû¸£¸é PD·Î Áø´Ü¹ÞÀº ȯÀÚ¿¡¼­´Â 76À¯ÇüÀÇ ¼ö¾× ´Ü¹éÁúÀÌ Á¤»óÀο¡ ºñÇØ ±¸Á¶ÀûÀ¸·Î º¯È­Çϰí ÀÖ´Â °ÍÀ¸·Î ¹àÇôÁ³½À´Ï´Ù. ÀÌ ¿¬±¸´Â ¶ÇÇÑÀÌ CSF ´Ü¹éÁúÀÌ Áúº´ Áø´Ü ¹× Ä¡·á¸¦À§ÇÑ ¹ÙÀÌ¿À ¸¶Ä¿·Î »ç¿ëÇÒ ¼ö ÀÖÀ½À» ½Ã»çÇÕ´Ï´Ù. PD´Â ÀÎÁö Àå¾Ö¿Í ¿îµ¿ ±â´É ÀúÇϸ¦ µ¿¹ÝÇÑ ½Å°æÅðÇ༺ ÁúȯÀÔ´Ï´Ù. 2022³â¿¡ ¹ßÇ¥µÈ ¼¼°èº¸°Ç±â±¸(WHO) º¸°í¼­¿¡ µû¸£¸é PDÀÇ À¯º´·üÀº Áö³­ 25³â°£ µÎ¹è·Î ´Ã¾úÀ¸¸ç 60¼¼ ÀÌ»óÀÇ ¼¼°è Àα¸ÀÇ ¾à 1%°¡ ¿µÇâÀ» ¹Þ¾Ò½À´Ï´Ù. À¯»çÇϰÔ, ¹ßÀÛÀ̳ª °£Áú »óÅ¿¡ Àִ ȯÀÚ¿¡¼­ ´Ü¹éÁú ¹× ¶ôÆ®»ê ¼öÄ¡¿Í °°Àº ¼ö¾× ¸Å°³º¯¼öÀÇ ÀϺΰ¡ º¯ÇÕ´Ï´Ù. µû¶ó¼­ ¹ßÀÛ°ú °£ÁúÀÇ Ä¡·á¿¡ ¼ö¾× ¸Å°³ º¯¼ö¸¦ »ç¿ëÇϱâ À§ÇØ ´Ù¾çÇÑ ¿¬±¸ °³¹ßÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, CSF¸¦ ÀÌ¿ëÇÑ ¾ËÃ÷ÇÏÀ̸Ӻ´ °ËÃâÀ» À§ÇÑ ´Ù¾çÇÑ CSF °ËÁ¤ÀÌ ½ÃÀå¿¡ ³ª¿Í ÀÖÀ½¿¡µµ ºÒ±¸Çϰí, °ËÃâ ¹× Ä¡·á ¸ñÀûÀÇ ¹ÙÀÌ¿À¸¶Ä¿¿¡ ´ëÇÑ ¿ä±¸´Â ÃæÁ·µÇÁö ¾Ê¾Ò½À´Ï´Ù. ¾ËÃ÷ÇÏÀ̸Ӻ´ ¹× PDÀÇ Áõ·Ê °ËÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¼ö¾× ´©ÃâÀÇ Áõ·Ê°¡ Áõ°¡ÇÒ ¼ö ÀÖÀ¸¹Ç·Î ¼ö¾× °ü¸® ÀåÄ¡ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ½Å°æÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÀÌ·¯ÇÑ ÁúȯÀÇ Ä¡·á¿¡ ¼ö¾× °ü¸® Á¦Ç°À» »ç¿ëÇϱâ À§ÇÑ ¿¬±¸°³¹ß Ȱµ¿¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå °³¿ä

¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸®´Â Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ³úô¼ö¾×(CSF) °ü¸®ÀÇ ¼¼°èÀû ½Ã³ª¸®¿À¿¡¼­ °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ½ÃÀåÀÔ´Ï´Ù. ÀÌ Áö¿ª¿¡¼­ ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀÇ ¼ºÀåÀº ³ëÀÎ Àα¸ Áõ°¡, °í±Þ ÀÇ·á±â±â¿¡ ´ëÇÑ ¼ö¿ä ¹× È¿À²ÀûÀÎ Ä¡·á¸¦ Á¦°øÇÏ´Â °Ç°­ °ü¸® ÀÎÇÁ¶ó Áõ°¡·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå ¼öÀͰú ¿¹Ãø(-2030³â)(US$Mn)

¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå ¼¼ºÐÈ­

¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº Á¦Ç°, ÃÖÁ¾ »ç¿ëÀÚ ¹× ±¹°¡·Î ±¸ºÐµË´Ï´Ù.

Á¦Ç°º°·Î ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº CSF ¼ÇÆ®¿Í CSF ¹è¼ö ½Ã½ºÅÛÀ¸·Î À̺е˴ϴÙ. 2022³â¿¡´Â CSF ¼ÇÆ® ºÎ¹®ÀÌ ´õ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î º¸¸é ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº º´¿ø, Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µîÀ¸·Î ±¸ºÐµË´Ï´Ù. º´¿ø ºÎ¹®Àº 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î º¸¸é ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµË´Ï´Ù. Áß±¹Àº 2022³â ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå Á¡À¯À²À» µ¶Á¡Çß½À´Ï´Ù.

B. Braun SE, Integra LifeSciences Holdings Corp, Medtronic Plc, Natus Medical Inc, Spiegelberg GmbH &Co KG´Â ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ´ë±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå »óȲ

  • ¾Æ½Ã¾ÆÅÂÆò¾ç PEST ºÐ¼®

Á¦5Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå - ÁÖ¿ä »ê¾÷ ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ³úô¼ö¾× ´©Ãâ Áõ·Ê Áõ°¡
    • ³úô¼ö¾×°ú °ü·ÃµÈ °úÁ¦ Áõ°¡¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °íÀåÀ̳ª ¿ÀÀÛµ¿ÀÇ À§Çè
  • ½ÃÀå ±âȸ
    • ½Å°æÁúȯ Ä¡·á¿¡ À־ÀÇ ¼ö¾× °ü¸®¿¡ ´ëÇÑ ÁÖ¸ñÀÇ °íÁ¶
  • ÇâÈÄÀÇ µ¿Çâ
    • ½º¸¶Æ® ³úô¼ö¾× ¼ÇÆ® °³¹ß
  • ¿µÇ⠺м®

Á¦6Àå ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå-¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®

  • ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀÇ ¼öÀÍ(2022³â-2030³â)

Á¦7Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå - ¼öÀͰú ¿¹Ãø(-2030³â) : Á¦Ç°º°

  • ½ÃÀå¼öÀÍ Á¡À¯À²(2022³â, 2030³â)
  • ¼ö¾× ¼ÇÆ®
  • ¼ö¾× ¹è¼ö ½Ã½ºÅÛ

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå - ¼öÀͰú ¿¹Ãø(-2030³â) : ÃÖÁ¾ »ç¿ëÀÚº°

  • ½ÃÀå¼öÀÍ Á¡À¯À²(2022³â, 2030³â)
  • º´¿ø
  • Áø·á¼Ò
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå : ±¹°¡º° ºÐ¼®

  • ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå : ±¹°¡º°
  • Áß±¹
  • ÀϺ»
  • Àεµ
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå : ¾÷°è Á¤¼¼

  • ¾Æ½Ã¾ÆÅÂÆò¾ç ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå¿¡¼­ÀÇ ¼ºÀå Àü·«(2020³â-2023³â)
  • ¹«±âÀû ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Medtronic Plc
  • Integra LifeSciences Holdings Corp
  • B. Braun SE
  • Natus Medical Inc
  • Spiegelberg GmbH & Co KG

Á¦12Àå ºÎ·Ï

BJH 24.05.23

The Asia Pacific cerebrospinal fluid management market was valued at US$ 389.53 million in 2022 and is expected to reach US$ 613.54 million by 2030; it is estimated to grow at a CAGR of 5.8% from 2022 to 2030.

Increasing Focus on CSF Management in Neurological Disease Treatments Fuels the Asia Pacific Cerebrospinal Fluid Management Market

CSF parameters are extensively evaluated as biomarkers of neurological disorders in adult patients. Circulating microRNAs in CSF are a promising class of biomarkers for the diagnosis of various neurological diseases. Neurological disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), epilepsy, and seizures often lead to altered CSF parameters. According to an article published in Nature, 76 CSF proteins were found to be structurally altered in patients that were diagnosed with PD when compared to normal individuals. The study also suggests that these CSF proteins can be used as biomarkers for the diagnosis or treatment of the disease. PD is a neurodegenerative disease associated with loss of cognitive impairment and motor function. According to the World Health Organization (WHO) report published in 2022, the prevalence of PD has doubled in the last 25 years, affecting ~1% of the global population aged more than 60 years. Similarly, a few of the CSF parameters such as protein and lactate levels are altered in patients suffering from seizure or status epilepticus. Therefore, various R&D activities are going on for using CSF parameters in the treatment of seizures or epilepsy. Further, despite the availability of various CSF assays for the detection of Alzheimer's disease using CSF in the market, there are unmet needs for biomarkers for detection and treatment purposes. As the detection of cases of Alzheimer's disease and PD increases, there is increase in demand for CSF management devices as the cases of CSF leaks may increases. Therefore, a rise in the prevalence of neurological disorders is fueling the research and development activities for the use of CSF management products in the treatment of these disorders.

Asia Pacific Cerebrospinal Fluid Management Market Overview

The Asia Pacific cerebrospinal fluid management is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Asia Pacific is the fastest-growing market for cerebrospinal fluid management in global scenario. The cerebrospinal fluid management market growth in this region is attributed to growing geriatric population, demand for advanced medical devices, and increasing healthcare infrastructures offering efficient treatments.

Asia Pacific Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)

Asia Pacific Cerebrospinal Fluid Management Market Segmentation

The Asia Pacific cerebrospinal fluid management market is segmented into product, end user and country.

Based on product, the Asia Pacific cerebrospinal fluid management market is bifurcated into CSF shunts and CSF drainage systems. The CSF shunts segment held a larger market share in 2022.

Based on end user, the Asia Pacific cerebrospinal fluid management market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest market share in 2022.

Based on country, the Asia Pacific cerebrospinal fluid management market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific cerebrospinal fluid management market share in 2022.

B. Braun SE, Integra LifeSciences Holdings Corp, Medtronic Plc, Natus Medical Inc, and Spiegelberg GmbH & Co KG are some of the leading companies operating in the Asia Pacific cerebrospinal fluid management market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Cerebrospinal Fluid Management Market Landscape

  • 4.1 Overview
  • 4.2 Asia Pacific PEST Analysis

5. Asia Pacific Cerebrospinal Fluid Management Market - Key Industry Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increasing Cases of Cerebrospinal Fluid Leaks
    • 5.1.2 Government Initiatives for Addressing Growing Challenges Associated with CSF
  • 5.2 Market Restraints
    • 5.2.1 Risk of Failure and Malfunctioning
  • 5.3 Market Opportunities
    • 5.3.1 Increasing Focus on CSF Management in Neurological Disease Treatments
  • 5.4 Future Trends
    • 5.4.1 Development of Smart Cerebrospinal Fluid Shunts
  • 5.5 Impact Analysis:

6. Cerebrospinal Fluid Management Market - Asia Pacific Market Analysis

  • 6.1 Asia Pacific Cerebrospinal Fluid Management Market Revenue (US$ Mn), 2022 - 2030

7. Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 - by Product

  • 7.1 Overview
  • 7.2 Asia Pacific Cerebrospinal Fluid Management Market Revenue Share, by Product 2022 & 2030 (%)
  • 7.3 CSF Shunts
    • 7.3.1 Overview
    • 7.3.2 CSF Shunts: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.3.3 Ventriculoperitoneal Shunts
      • 7.3.3.1 Overview
      • 7.3.3.2 Ventriculoperitoneal Shunts: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.3.4 Ventriculoatrial Shunts
      • 7.3.4.1 Overview
      • 7.3.4.2 Ventriculoatrial Shunts: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.3.5 Ventriculopleural Shunts
      • 7.3.5.1 Overview
      • 7.3.5.2 Ventriculopleural Shunts: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.3.6 Lumboperitoneal Shunts
      • 7.3.6.1 Overview
      • 7.3.6.2 Lumboperitoneal Shunts: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 CSF Drainage Systems
    • 7.4.1 Overview
    • 7.4.2 CSF Drainage Systems: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.4.3 External Ventricular Drainage (EVD) Systems
      • 7.4.3.1 Overview
      • 7.4.3.2 External Ventricular Drainage (EVD) Systems: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.4.4 Lumbar Drainage (LD) Systems
      • 7.4.4.1 Overview
      • 7.4.4.2 Lumbar Drainage (LD) Systems: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 - by End User

  • 8.1 Overview
  • 8.2 Asia Pacific Cerebrospinal Fluid Management Market Revenue Share, by End User 2022 & 2030 (%)
  • 8.3 Hospitals
    • 8.3.1 Overview
    • 8.3.2 Hospitals: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Clinics
    • 8.4.1 Overview
    • 8.4.2 Clinics: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Ambulatory Surgical Centers
    • 8.5.1 Overview
    • 8.5.2 Ambulatory Surgical Centers: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: Asia Pacific Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Cerebrospinal Fluid Management Market - Country Analysis

  • 9.1 Overview
      • 9.1.1.1 Asia Pacific Cerebrospinal Fluid Management Market, by Country
      • 9.1.1.2 China
        • 9.1.1.2.1 Overview
        • 9.1.1.2.2 China: Asia Pacific Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.2.3 China: Asia Pacific Cerebrospinal Fluid Management Market, by Product
        • 9.1.1.2.3.1 China: Asia Pacific Cerebrospinal Fluid Management Market, by CSF Shunts
        • 9.1.1.2.3.2 China: Asia Pacific Cerebrospinal Fluid Management Market, by CSF Drainage Systems
        • 9.1.1.2.4 China: Asia Pacific Cerebrospinal Fluid Management Market, by End User
      • 9.1.1.3 Japan
        • 9.1.1.3.1 Overview
        • 9.1.1.3.2 Japan: Asia Pacific Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.3.3 Japan: Asia Pacific Cerebrospinal Fluid Management Market, by Product
        • 9.1.1.3.3.1 Japan: Asia Pacific Cerebrospinal Fluid Management Market, by CSF Shunts
        • 9.1.1.3.3.2 Japan: Asia Pacific Cerebrospinal Fluid Management Market, by CSF Drainage Systems
        • 9.1.1.3.4 Japan: Asia Pacific Cerebrospinal Fluid Management Market, by End User
      • 9.1.1.4 India
        • 9.1.1.4.1 Overview
        • 9.1.1.4.2 India: Asia Pacific Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.4.3 India: Asia Pacific Cerebrospinal Fluid Management Market, by Product
        • 9.1.1.4.3.1 India: Asia Pacific Cerebrospinal Fluid Management Market, by CSF Shunts
        • 9.1.1.4.3.2 India: Asia Pacific Cerebrospinal Fluid Management Market, by CSF Drainage Systems
        • 9.1.1.4.4 India: Asia Pacific Cerebrospinal Fluid Management Market, by End User
      • 9.1.1.5 Australia
        • 9.1.1.5.1 Overview
        • 9.1.1.5.2 Australia: Asia Pacific Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.5.3 Australia: Asia Pacific Cerebrospinal Fluid Management Market, by Product
        • 9.1.1.5.3.1 Australia: Asia Pacific Cerebrospinal Fluid Management Market, by CSF Shunts
        • 9.1.1.5.3.2 Australia: Asia Pacific Cerebrospinal Fluid Management Market, by CSF Drainage Systems
        • 9.1.1.5.4 Australia: Asia Pacific Cerebrospinal Fluid Management Market, by End User
      • 9.1.1.6 South Korea
        • 9.1.1.6.1 Overview
        • 9.1.1.6.2 South Korea: Asia Pacific Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.6.3 South Korea: Asia Pacific Cerebrospinal Fluid Management Market, by Product
        • 9.1.1.6.3.1 South Korea: Asia Pacific Cerebrospinal Fluid Management Market, by CSF Shunts
        • 9.1.1.6.3.2 South Korea: Asia Pacific Cerebrospinal Fluid Management Market, by CSF Drainage Systems
        • 9.1.1.6.4 South Korea: Asia Pacific Cerebrospinal Fluid Management Market, by End User
      • 9.1.1.7 Rest of Asia Pacific
        • 9.1.1.7.1 Overview
        • 9.1.1.7.2 Rest of Asia Pacific: Asia Pacific Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.7.3 Rest of Asia Pacific: Asia Pacific Cerebrospinal Fluid Management Market, by Product
        • 9.1.1.7.3.1 Rest of Asia Pacific: Asia Pacific Cerebrospinal Fluid Management Market, by CSF Shunts
        • 9.1.1.7.3.2 Rest of Asia Pacific: Asia Pacific Cerebrospinal Fluid Management Market, by CSF Drainage Systems
        • 9.1.1.7.4 Rest of Asia Pacific: Asia Pacific Cerebrospinal Fluid Management Market, by End User

10. Asia Pacific Cerebrospinal Fluid Management Market -Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in The Asia Pacific Cerebrospinal Fluid Management Market, 2020-2023
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Organic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Medtronic Plc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Integra LifeSciences Holdings Corp
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 B. Braun SE
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Natus Medical Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Spiegelberg GmbH & Co KG
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments

12. Appendix

  • 12.1 About Us
  • 12.2 Glossary of Terms
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦